IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
1.080
+0.095 (9.59%)
At close: Sep 15, 2025, 4:00 PM EDT
1.080
0.00 (0.00%)
After-hours: Sep 15, 2025, 4:39 PM EDT
IceCure Medical Revenue
IceCure Medical had revenue of $525.00K in the quarter ending June 30, 2025, a decrease of -48.07%. This brings the company's revenue in the last twelve months to $2.79M, down -16.46% year-over-year. In the year 2024, IceCure Medical had annual revenue of $3.29M with 1.92% growth.
Revenue (ttm)
$2.79M
Revenue Growth
-16.46%
P/S Ratio
19.81
Revenue / Employee
$42,227
Employees
66
Market Cap
84.94M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.29M | 62.00K | 1.92% |
Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
Dec 31, 2020 | 3.87M | 2.21M | 132.76% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ICCM News
- 8 hours ago - IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications - PRNewsWire
- 7 days ago - Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate - PRNewsWire
- 11 days ago - IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy - PRNewsWire
- 4 weeks ago - IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - IceCure Reports Financial & Operational Results for the First Half of 2025 - PRNewsWire
- 5 weeks ago - IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025 - PRNewsWire
- 6 weeks ago - IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million - PRNewsWire
- 7 weeks ago - IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation - PRNewsWire